Evidence map›Paper›PMID 20463897›Full record

ArticlePloS one2010

Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats.

Ricardo Valladares, Dhyana Sankar, Nan Li, Emily Williams, Kin-Kwan Lai, Asmaa Sayed Abdelgeliel, Claudio F Gonzalez, Clive H Wasserfall, Joseph Larkin, Desmond Schatz and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03032354 (Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial), which is not on this map. Cited by 151 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03032354 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial

TypeinterventionalSponsorMedical University of WarsawRan2017 to 2018Enrolled96ConditionsDiabetes Mellitus, Type 1ArmsLactobacillus rhamnosus GG and Bifidobacterium lactis BB12, Placebo, (Placebo group)
3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 1 synthesis or guideline pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Lack of effect ofBMJ open diabetes research & care · 2021
    Trial
  3. Effects ofBMJ open · 2017
    Trial
  4. Review
  5. Review
  6. The Role of ProbioticsInternational journal of molecular sciences · 2026
    Review
  7. Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026
    Review
  8. Article
  9. Strain-resolved biology ofFrontiers in veterinary science · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Metabolites · 2025
    Article
  14. Review
  15. Assessment of ImmobilizedFoods (Basel, Switzerland) · 2024
    Article
  16. Article
  17. Article
  18. Erucic acid utilization byFrontiers in microbiology · 2024
    Article
  19. Review
  20. The Sdp-SH3b2 domain contained inFrontiers in immunology · 2024
    Article

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Ricardo ValladaresDepartment of Microbiology and Cell Science, University of Florida, Gainesville, Florida, United States of America.
Dhyana Sankar
Nan Li
Emily Williams
Kin-Kwan Lai
Asmaa Sayed Abdelgeliel
Claudio F Gonzalez
Clive H Wasserfall
Joseph Larkin
Desmond Schatz
Mark A Atkinson
Eric W Triplett
Josef Neu
Graciela L Lorca
University of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe intestinal epithelium is a barrier that composes one of the most immunologically active surfaces of the body due to constant exposure to microorganisms as well as an infinite diversity of food antigens. Disruption of intestinal barrier function and aberrant mucosal immune activation have been implicated in a variety of diseases within and outside of the gastrointestinal tract. With this model in mind, recent studies have shown a link between diet, composition of intestinal microbiota, and type 1 diabetes pathogenesis. In the BioBreeding rat model of type 1 diabetes, comparison of the intestinal microbial composition of diabetes prone and diabetes resistant animals found Lactobacillus species were negatively correlated with type 1 diabetes development. Two species, Lactobacillus johnsonii and L. reuteri, were isolated from diabetes resistant rats. In this study diabetes prone rats were administered pure cultures of L. johnsonii or L. reuteri isolated from diabetes resistant rats to determine the effect on type 1 diabetes development. METHODOLOGY/PRINCIPAL: Findings Results Rats administered L. johnsonii, but not L. reuteri, post-weaning developed type 1 diabetes at a protracted rate. Analysis of the intestinal ileum showed administration of L. johnsonii induced changes in the native microbiota, host mucosal proteins, and host oxidative stress response. A decreased oxidative intestinal environment was evidenced by decreased expression of several oxidative response proteins in the intestinal mucosa (Gpx1, GR, Cat). In L. johnsonii fed animals low levels of the pro-inflammatory cytokine IFNgamma were correlated with low levels of iNOS and high levels of Cox2. The administration of L. johnsonii also resulted in higher levels of the tight junction protein claudin.

conclusionsIt was determined that the administration of L. johnsonii isolated from BioBreeding diabetes resistant rats delays or inhibits the onset of type 1 diabetes in BioBreeding diabetes prone rats. Taken collectively, these data suggest that the gut and the gut microbiota are potential agents of influence in type 1 diabetes development. These data also support therapeutic efforts that seek to modify gut microbiota as a means to modulate development of this disorder.

Indexed as

AnimalsCytokinesDiabetes Mellitus, Type 1Feeding BehaviorFemaleGastrointestinal TractIncidenceInflammation MediatorsKaplan-Meier EstimateLactobacillusMaleMembrane ProteinsMetagenomeOxidative StressRatsRats, Inbred BBCytokinesInflammation MediatorsMembrane ProteinsRNA, Messenger

Identifiers

PMID20463897
PMCPMC2865539
OpenAlexW2042148950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.